Monoclonal antibodies in advanced B-cell lymphomas

ONCOLOGY

Volumn 24, Issue 2, 2010, Pages

  Ujjani, Chaitra ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AME 133; AZRERRA; BENDAMUSTINE; BI SPECIFIC T CELL ENGAGER MOLECULE; BLINATUMUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACETUMUMAB; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GA 101; GALIXIMAB; HCD 122; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INOTUZUMAB OZOGAMICIN; LEXATUMUMAB; LUCATUMUMAB; LUMILIXIMAB; MAPATUMUMAB; MEDI 538; MILATUZUMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; MT 110; OFATUMUMAB; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; SGN 40; TOSITUMOMAB I 131; TRU 016; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

ADVANCED CANCER; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CEREBELLAR ATAXIA; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMA; CONFUSION; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY REACTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; META ANALYSIS; METABOLIC ACIDOSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REFRACTORY PERIOD; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 77949353196     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004.
2. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regular complement-mediated cell lysis. Blood 95:3900-3908, 2000.
3. Terui Y, Sakurai T, Mishima Y, et al: Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Science 97:72-79, 2006.
4. Weng W, Levy R: Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003.
5. Clynes RA, Towers TL, Persta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 6:443-446, 2000.
6. 3RIIIa gene. Blood 99:754-758, 2002.
7. Stolz C, Hess G, Hahnel P, et al: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 112:3312-3321, 2008.
8. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 101:4279-4284, 2003.
9. Wilson W, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008.
10. Winter J, Weller E, Horning S, et al: Prognostic significance of bcl-6 protein expression in DLBCL treated with CHOP or RCHOP: A prospective correlative study. Blood 107:4207-4213, 2006.
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
12. Davis T, Grillo-Lopez A, White C, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkins lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000.
13. Piro L, White C, Grillo-Lopez A, et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. Ann Oncol 10:655-661, 1999.
14. Colombat P, Brousse N, Morschhauser F, et al: Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma: Survival analyses with extended follow-up of 7 years (abstract 486). Blood 108, 2006.
15. Witzig T, Vukov A, Habermann T, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkins lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103-1108, 2005.
16. Hainsworth J, Litchy S, Barton J, et al: Single-agent rituximab as front-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003.
17. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008.
18. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005.
19. Herold M, Haas A, Sroch S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An Eastern German Study Group hematology and oncology study. J Clin Oncol 25:1986-1992, 2007.
20. Van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkins lymphoma in patients with and without rituximab during induction: Results of a prospective randomized phase III intergroup trial. Blood 108:3295-3301, 2006.
21. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004.
22. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005.
23. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002.
24. Feugier P, van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Group dEdute des Lymphomes de lAdulte. J Clin Oncol 23:4117-4126, 2005.
25. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006.
26. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomized controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008.
27. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006.
28. Poeschel V, Nickelsen M, Hanel M, et al: Dose-dense Rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma: Results of a phase I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (abstract 2738). Blood 108, 2006.
29. Cunningham D, Smith P, Mouncey P, et al: A phase III trial comparing R-CHOP-14 and R-CHOP-21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkins lymphoma (abstract 8506). J Clin Oncol 27(15S):435s, 2009.
30. Hainsworth JD: First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkins lymphoma. Semin Oncol 30:9-15, 2003.
31. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004.
32. Ghielmini M, Hsu Schmitz S, Martinelli G, et al: Long-term follow-up of patients with follicular lymphoma receiving single agent rituximab at two different schedules in study SAKK 35/98 (abstract 8512). J Clin Oncol 27(15S):437s, 2009.
33. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 108:4003-4008, 2006.
34. Hochster H, Weller E, Randy D, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 27:1609-1614, 2009.
35. Vidal L, Gafter-Gvili A, Leibovici L, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 101:248-255, 2009.
36. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106(suppl):106a, 2005.
37. Hochster HS, Weller E, Gascoyne RD, et al: Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial (abstract 8004). J Clin Oncol 25(18S):8004, 2009.
38. Van Oers MHJ,Van Glabbeke M, Baila L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkins lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study (abstract 836). Blood 112, 309-310, 2008.
39. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkins lymphoma: A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005.
40. Rituximab prescribing information, September 2009. Available at http://www.gene.com/gene/products/information/pdf/rituxan-rescribing.pdf. Accessed Jan 9, 2010.
41. Hagenbeek A, Gadeberg O, Johnson P, et al: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial. Blood 111:5486-5495, 2008.
42. Genmab products in development, 2009. Retrieved from http://www.genmab. com/en/Science%20And%20Research/Products%20in%20Development/Ofatumumab.aspx. Accessed Jan 9, 2010.
43. Osterborg A, Kipps T, Mayer J: Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for subjects with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial (abstract 328). Blood 112, 2008.
44. Morschhauser F, Leonard JP, Fayad L, et al: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkins lymphoma: Phase I/II results. J Clin Oncol 27:3346-3353, 2009.
45. Salles GA, Morschhauser F, Cartron GC, et al: A phase I/II study of RO5072759 (GA-101) in patients with relapsed/refractory CD20+ malignant disease (abstract 234). Blood 112, 2008.
46. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkins lymphoma. J Clin Oncol 21:3051-3059, 2003.
47. Leonard JP, Schuster SJ, Emmanouilides C, et al: Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase II study in recurrent, indolent, non-Hodgkins lymphoma. Cancer 113:2714-2723, 2008.
48. Strauss SJ, Morschhauser F, Rech J, et al: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkins lymphoma. J Clin Oncol 24:3880-3886, 2006.
49. Micallef IN, Maurer MJ, Nikcevich DA, et al: A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (abstract 8500). J Clin Oncol 26(15S):454s, 2008.
50. Byrd J, OBrien S, Flinn I, et al: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 13:4448-4455, 2007.
51. Byrd JC, Castro JE, Flinn IW, et al: Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study (abstract 7003). J Clin Oncol 26(15S):372s, 2008.
52. Wierda W, OBrien, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005.
53. Czuczman MS, Thall A, Witzig TE, et al: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23:4390-4398, 2005.
54. Leonard JP, Freidberg JW, Younes A, et al: A phase I/II study of galiximab (an anti-CD80 antibody) in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol 18:1216-1223, 2007.
55. Czuczman M, Leonard J, Johnson J, et al: FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: Phase II trial of extended induction galiximab plus rituximab (abstract 1003). Blood 112, 2008.
56. Advani R, Forero-Torres A, Furman R, et al: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkins lymphoma. J Clin Oncol 27:4371-4377, 2009.
57. Weng W-K, Tong X, Luqman M, et al: A fully human anti-CD40 antagonistic antibody, CHIR-12.12, inhibit the proliferation of human B cell non-Hodgkins lymphoma (abstract 3279). Blood 104, 2004.
58. Keating M, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
59. Hillmen P, Skotnicki A, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007.
60. Wierda W, OBrien S, Ferrajoli A, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL (abstract 628). Blood 110, 2007.
61. Czuczman M, Maddipatla S, Knight J, et al: In vitro synergistic anti-tumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non-Hodgkins lymphoma cells (NHL) (abstract 1475). Blood 106, 2005.
62. Younes A, Vose J, Zelenetz A, et al: Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkins lymphoma (NHL) (abstract 489). Blood 106:, 2005.
63. Hayden-Ledbetter M, Cerveny C, Esping E, et al: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15:1078-0432, 2009.
64. Baum P, Ceverny C, Gordon B, et al: Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkins lymphoma (abstract 8571). J Clin Oncol 27(15S):451s, 2009.
65. Andritsos L, Furman R, Flinn IW, et al: A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL (abstract 3017). J Clin Oncol 27(15S):133s, 2009.
66. Bargou R, Leo E, Zumagier G, et al: Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 321:974-977, 2008.
67. Polson A, Bennett F, Chen Y, et al: Development and therapeutic potential of an anti-CD79b antibody-drug conjugate, Anti-CD79b-Vc-MMAE, for the treatment of non-Hodgkins lymphoma (abstract 2618). Blood 112, 2008.
68. Fayad L, Patel H, Verhoef G, et al: Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose cohort of a phase I study (abstract 2711). Blood 108, 2006.
69. Fayad L, Patel H, Verhoef G, et al: Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase I/II study (abstract 266). Blood 112, 2008.
70. Witzig TE, Linn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radiotherapy in patients with rituximab-refractory follicular non-Hodgkins lymphoma. J Clin Oncol 20:3262-3269, 2002.
71. Witzig TE, Gordon LI, Camarillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkins lymphoma. J Clin Oncol 20:2453-2463, 2002.
72. Morschhauser F, Radford J, van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-labeled ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008.
73. Krishnan A, Anemone A, Fung HC, et al: Phase II trial of a transplantation regimen of yttrium-90-labeled ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkins lymphoma. J Clin Oncol 26:90-95, 2008.
74. Morschhauser F, Elide TM, Hugli D, et al: Efficacy and safety of yttrium-90-labeled ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110:54-58, 2007.
75. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkins lymphoma. J Clin Oncol 19:3918-3928, 2001.
76. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005.
77. Kaminski MS, Tuck M, Estes J, et al: 131I- tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 353:441-449, 2005.
78. Press O, Unger J, Maloney D, et al: An update of a phase II trial of CHOP followed by tositumomab/iodine I-131 tositumomab (Bexxar® ) for front-line treatment of advanced stage, follicular lymphoma: SWOG 9911 (abstract 352). Blood 106:352, 2005.
79. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkins lymphoma. J Clin Oncol 21:1263-1270, 2003.